Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients.
BACKGROUND
Indoleamine (2,3)-dioxygenase (IDO) catalyses the initial, rate-limiting step in the degradation of the essential amino acid tryptophan. Via tryptophan deprivation, IDO activity suppresses T cell proliferation and differentiation and is thought to be a fundamental immune escape mechanism for tumor cells.


OBJECTIVE
To investigate the potential role of tryptophan degradation as a prognostic marker, serum tryptophan and kynurenine concentrations and the kynurenine-to-tryptophan ratio (kyn/trp) in 87 patients with malignant melanoma were compared to the course of the disease and to concentrations of the immune activation marker neopterin.


RESULTS
Compared to 49 healthy volunteers, the melanoma patients presented with lower tryptophan levels due to accelerated degradation. This was especially true for the subgroups of patients with distant metastases (p = 0.01), though not in patients with lymph node metastases or in patients who had not yet progressed. There existed a positive correlation between kyn/trp and neopterin concentrations (r(s) = 0.587, p <0.001). In patients who died due to dissemination of the tumor, median tryptophan concentrations were significantly decreased (p = 0.006) and kyn/trp (p = 0.03) and neopterin concentrations (p = 0.002) were higher compared to survivors. In addition, lower tryptophan concentrations as well as higher kyn/trp and neopterin concentrations predicted a shorter survival.


CONCLUSIONS
Decreased serum tryptophan concentrations and elevated serum neopterin levels can be used as predictive markers for the future course in melanoma patients. Moreover, our data support previous speculations that a higher degree of IDO expression could play a crucial role for tumor progression.
Weinlich
Georg
G
Clinical Department of Dermatology and Venerology, Innsbruck Medical University, Innsbruck, Austria. georg.weinlich@uibk.ac.at
Murr
Christian
C
Richardsen
Laura
L
Winkler
Christiana
C
Fuchs
Dietmar
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D019798:Neopterin / Q000097:blood; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D014364:Tryptophan / Q000097:blood*
D014408:Biomarkers, Tumor; D019798:Neopterin; D014364:Tryptophan